{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:20:45Z","timestamp":1790767245122,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T00:00:00Z","timestamp":1535068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ctrv.2018.08.008","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T22:22:40Z","timestamp":1534803760000},"page":"190-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Multiple modes of action of eribulin mesylate: Emerging data and clinical implications"],"prefix":"10.1016","volume":"70","author":[{"given":"Javier","family":"Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"Patrick","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Littlefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2018.08.008_b0005","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2018.08.008_b0010","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2018.08.008_b0015","unstructured":"Halaven (eribulin mesylate) injection [prescribing information]. Woodcliff Lake, NJ: Eisai Inc.; 2016."},{"key":"10.1016\/j.ctrv.2018.08.008_b0020","unstructured":"Halaven 0.44 mg\/ml solution for injection [summary of product characteristics]. Hertfordshire, UK: Eisai Europe Limited."},{"key":"10.1016\/j.ctrv.2018.08.008_b0025","first-page":"1611","article-title":"Broad spectrum preclinical antitumor activity of eribulin (Halaven\u00ae): optimal effectiveness under intermittent dosing conditions","volume":"32","author":"Towle","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2018.08.008_b0030","first-page":"1553","article-title":"Antimitotic and non-mitotic effects of eribulin mesilate in soft tissue sarcoma","volume":"36","author":"Kawano","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2018.08.008_b0035","first-page":"1013","article-title":"In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B","volume":"61","author":"Towle","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.08.008_b0040","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/pbc.24517","article-title":"Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program","volume":"60","author":"Kolb","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2018.08.008_b0045","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1351\/pac198658050701","article-title":"Halichondrins\u2014antitumor polyether macrolides from a marine sponge","volume":"58","author":"Hirata","year":"1986","journal-title":"Pure Appl Chem"},{"key":"10.1016\/j.ctrv.2018.08.008_b0050","doi-asserted-by":"crossref","first-page":"15882","DOI":"10.1016\/S0021-9258(18)98491-7","article-title":"Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data","volume":"266","author":"Bai","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2018.08.008_b0055","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0006-2952(93)90079-C","article-title":"Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin","volume":"45","author":"Ludue\u00f1a","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ctrv.2018.08.008_b0060","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","article-title":"The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth","volume":"4","author":"Jordan","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2018.08.008_b0065","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.cub.2016.04.053","article-title":"Termination of protofilament elongation by eribulin induces lattice defects that promote microtubule catastrophes","volume":"26","author":"Doodhi","year":"2016","journal-title":"Curr Biol"},{"key":"10.1016\/j.ctrv.2018.08.008_b0070","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/cas.12488","article-title":"Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models","volume":"105","author":"Funahashi","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2018.08.008_b0075","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/bjc.2014.80","article-title":"Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states","volume":"110","author":"Yoshida","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2018.08.008_b0080","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","article-title":"Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389","volume":"64","author":"Kuznetsov","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.08.008_b0085","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-08-0095","article-title":"Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase","volume":"7","author":"Okouneva","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2018.08.008_b0090","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/bi901810u","article-title":"Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability","volume":"49","author":"Smith","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.ctrv.2018.08.008_b0095","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/0008-5472.CAN-10-1874","article-title":"Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions","volume":"71","author":"Towle","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.08.008_b0100","unstructured":"Kawano S, Asano M, Adachi Y, Matsui J. Antimitotic effect and complex of non-mitotic effect on tumor biology of eribulin mesilate in soft tissue sarcoma models. Presented at: Japanese Cancer Association, October 6\u20138, 2016, Yokohama, Japan."},{"key":"10.1016\/j.ctrv.2018.08.008_b0105","doi-asserted-by":"crossref","unstructured":"Ozawa Y, Okamoto K, Adachi M, Asano K, Tabata Y, Funahashi J, et al. Supression of metastasis and improvement of drug distribution by eribulin mesylate. Presented at: EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, November 18\u201321, 2014, Spain, Barcelona.","DOI":"10.1016\/S0959-8049(14)70162-5"},{"key":"10.1016\/j.ctrv.2018.08.008_b0110","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2613.2009.00651.x","article-title":"Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies","volume":"90","author":"Kanthou","year":"2009","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.ctrv.2018.08.008_b0115","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1016\/j.ejca.2006.06.019","article-title":"Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development","volume":"42","author":"Kruczynski","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2018.08.008_b0120","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/0959-8049(93)90082-Q","article-title":"Vinca alkaloids: anti-vascular effects in a murine tumour","volume":"29A","author":"Hill","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2018.08.008_b0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2045-824X-6-3","article-title":"Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro","volume":"6","author":"Agoulnik","year":"2014","journal-title":"Vasc Cell"},{"key":"10.1016\/j.ctrv.2018.08.008_b0130","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc3447","article-title":"Regulatory networks defining EMT during cancer initiation and progression","volume":"13","author":"De Craene","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2018.08.008_b0135","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2174\/1381612821666141211115611","article-title":"The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links","volume":"21","author":"Liu","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ctrv.2018.08.008_b0140","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1158\/0008-5472.CAN-16-3292","article-title":"Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas","volume":"77","author":"Dongre","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.08.008_b0145","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/1078-0432.CCR-13-3173","article-title":"Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis","volume":"21","author":"Jung","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2018.08.008_b0150","doi-asserted-by":"crossref","first-page":"e106131","DOI":"10.1371\/journal.pone.0106131","article-title":"Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells","volume":"9","author":"Dezs\u0151","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2018.08.008_b0155","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/bjc.2014.136","article-title":"Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells","volume":"110","author":"Yang","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2018.08.008_b0160","doi-asserted-by":"crossref","unstructured":"Kaul R, Risinger AL, Mooberry S. Eribulin differentially disrupts TGF-\u03b2 signaling pathway in BT-549 and HCC1937 breast cancer cell lines. Presented at: San Antonio Breast Cancer Symposium, December 5\u20139, 2017, San Antonio, TX, USA. Poster P5-04-04.","DOI":"10.1158\/1538-7445.SABCS17-P5-04-04"},{"key":"10.1016\/j.ctrv.2018.08.008_b0165","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.18632\/oncotarget.23798","article-title":"Regulation of E-cadherin localization by microtubule targeting agents: rapid promotion of cortical E-cadherin through p130Cas\/Src inhibition by eribulin","volume":"9","author":"Dybdal-Hargreaves","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2018.08.008_b0170","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.3892\/or.2016.5189","article-title":"Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition","volume":"36","author":"Kitahara","year":"2016","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2018.08.008_b0175","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.21873\/anticanres.12604","article-title":"Broad-spectrum preclinical antitumor activity of eribulin (Halaven\u00ae): combination with anticancer agents of differing mechanisms","volume":"38","author":"Asano","year":"2018","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2018.08.008_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/jcm5020013","article-title":"Epithelial-mesenchymal transition and breast cancer","volume":"5","author":"Wu","year":"2016","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctrv.2018.08.008_b0185","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrc1370","article-title":"Dissecting the metastatic cascade","volume":"4","author":"Pantel","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2018.08.008_b0190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc2620","article-title":"Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits","volume":"9","author":"Polyak","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2018.08.008_b0195","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ajpath.2014.10.006","article-title":"Characterization of a new small bowel adenocarcinoma cell line and screening of anti-cancer drug against small bowel adenocarcinoma","volume":"185","author":"Suzuki","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2018.08.008_b0200","doi-asserted-by":"crossref","first-page":"12465","DOI":"10.1038\/srep12465","article-title":"Blockade of Wnt\/\u03b2-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype","volume":"5","author":"Jang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2018.08.008_b0205","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12282-014-0580-9","article-title":"Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells","volume":"23","author":"Kurebayashi","year":"2016","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ctrv.2018.08.008_b0210","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1097-2765(00)80400-1","article-title":"Microtubule binding to Smads may regulate TGF\u03b2 activity","volume":"5","author":"Dong","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.ctrv.2018.08.008_b0215","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1091\/mbc.e06-12-1064","article-title":"Cx43 mediates TGF-\u03b2 signaling through competitive Smads binding to microtubules","volume":"18","author":"Dai","year":"2007","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.ctrv.2018.08.008_b0220","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1007\/s00018-012-1122-2","article-title":"EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness","volume":"69","author":"S\u00e1nchez-Till\u00f3","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ctrv.2018.08.008_b0225","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fnmol.2015.00044","article-title":"The axonal cytoskeleton: from organization to function","volume":"8","author":"Kevenaar","year":"2015","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.ctrv.2018.08.008_b0230","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1158\/0008-5472.CAN-10-4184","article-title":"Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice","volume":"71","author":"Wozniak","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2018.08.008_b0235","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s12640-013-9394-3","article-title":"Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy","volume":"24","author":"Wozniak","year":"2013","journal-title":"Neurotox Res"},{"key":"10.1016\/j.ctrv.2018.08.008_b0240","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neuro.2013.05.008","article-title":"Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy","volume":"37","author":"LaPointe","year":"2013","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ctrv.2018.08.008_b0245","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10549-013-2574-2","article-title":"Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy","volume":"140","author":"Vahdat","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2018.08.008_b0250","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2008.17.7618","article-title":"Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"27","author":"Vahdat","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.08.008_b0255","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/bjc.2016.122","article-title":"In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab","volume":"114","author":"Ueda","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2018.08.008_b0260","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4172\/2167-7964.1000250","article-title":"Assessing oxygenation response to eribulin in a patient with recurrent breast cancer after resistance to endocrine therapy","volume":"6","author":"Ueda","year":"2017","journal-title":"OMICS J Radiol"},{"key":"10.1016\/j.ctrv.2018.08.008_b0265","unstructured":"Yardley DA, Chandra P, Hart L, Wright G, Ward P, Mani A, et al. A phase II randomized study with eribulin\/cyclophosphamide (ErC) or docetaxel\/cyclophosphamide (TC) as neoadjuvant theray in HER2-negative breast cancer: Final efficacy analysis and results of correlative studies. Presented at: San Antonio Breast Cancer Symposium, December 8\u201312, 2015, San Antonio, TX, USA."},{"key":"10.1016\/j.ctrv.2018.08.008_b0270","unstructured":"Goto W, Kashiwagi S, Asano Y, Kurata K, Morisaki T, Noda S, et al. Clinical verification of antitumor autoimmune response in eribulin chemotherapy for breast cancer. Presented at: Annual Meeting of the American Association for Cancer Research, April 16\u201320, 2016, New Orleans, LA, USA."},{"key":"10.1016\/j.ctrv.2018.08.008_b0275","first-page":"401","article-title":"Mesenchymal-epithelial transition and tumor vascular remodeling in eribulin chemotherapy for breast cancer","volume":"38","author":"Kashiwagi","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2018.08.008_b0280","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1038\/ncomms6241","article-title":"Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression","volume":"5","author":"Chen","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2018.08.008_b0285","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/1878-0261.12095","article-title":"EMT and inflammation: inseparable actors of cancer progression","volume":"11","author":"Suarez-Carmona","year":"2017","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctrv.2018.08.008_b0290","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.2016.71.6605","article-title":"Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine","volume":"35","author":"Demetri","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.08.008_b0295","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1074\/mcp.M110.000240","article-title":"Integrated proteomics and genomics analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug","volume":"9","author":"Yang","year":"2010","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.ctrv.2018.08.008_b0300","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.hoc.2013.07.005","article-title":"Angiosarcomas and other sarcomas of endothelial origin","volume":"27","author":"Cioffi","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ctrv.2018.08.008_b0305","unstructured":"Prat A, Ortega V, Pare L, Galvan P, Oliveira M, Nuciforo P, et al. Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study. Presented at: San Antonio Breast Cancer Symposium, December 8\u201312, 2015, San Antonio, TX, USA."},{"key":"10.1016\/j.ctrv.2018.08.008_b0310","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.08.008_b0315","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: Prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.ctrv.2018.08.008_b0320","doi-asserted-by":"crossref","unstructured":"Kobayashi K, Ito Y, Shibayama T, Fukada I, Ishizuka N, Horii R, et al. Eribulin mesylate may improve the sensitivity of endocrine therapy in metastatic breast cancer. Presented at: European Society for Medical Oncology, October 7\u201311, 2016, Copenhagan, Denmark.","DOI":"10.1093\/annonc\/mdw365.23"},{"issue":"Suppl","key":"10.1016\/j.ctrv.2018.08.008_b0325","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1016\/j.semcancer.2015.03.008","article-title":"Tissue invasion and metastasis: molecular, biological and clinical perspectives","volume":"35","author":"Jiang","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ctrv.2018.08.008_b0330","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1470-2045(18)30147-5","article-title":"Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial","volume":"19","author":"Pernas","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2018.08.008_b0335","unstructured":"U.S. FDA grants Fast Track designation for Polyphor's innovative immuno-oncology candidate balixafortide in combination with eribulin as third line therapy for metastatic breast cancer [press release]. 19 April 2018. Available from: https:\/\/www.polyphor.com\/news\/corporate-news-details\/?newsid=1689641 [accessed 10 August 2018]."},{"key":"10.1016\/j.ctrv.2018.08.008_b0340","unstructured":"ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/ [accessed 10 August 2018]."},{"key":"10.1016\/j.ctrv.2018.08.008_b0345","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2016.12.018","article-title":"Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial","volume":"75","author":"Wiemer","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2018.08.008_b0350","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(11)70230-3","article-title":"Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes","volume":"12","author":"Sch\u00f6ffski","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2018.08.008_b0355","doi-asserted-by":"crossref","first-page":"e115103","DOI":"10.1371\/journal.pone.0115103","article-title":"The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis","volume":"9","author":"Mao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2018.08.008_b0360","doi-asserted-by":"crossref","first-page":"e0170634","DOI":"10.1371\/journal.pone.0170634","article-title":"Use of tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer","volume":"12","author":"Kashiwagi","year":"2017","journal-title":"PLoS One"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218301439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737218301439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:20:15Z","timestamp":1759656015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737218301439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":72,"alternative-id":["S0305737218301439"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.08.008","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple modes of action of eribulin mesylate: Emerging data and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2018.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}